Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET

Company Participants

Edward Chung - Head, IR

Norman Schwartz - CEO

Ilan Daskal - EVP and CFO

Andy Last - EVP and COO

Simon May - President, Life Science Group

Dara Wright - President, Clinical Diagnostics Group

Conference Call Participants

Brandon Couillard - Jefferies

Patrick Donnelly - Citi

Jack Meehan - Nephron

Tim Daley - Wells Fargo

Conor McNamara - RBC Capital

Operator

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to the Bio-Rad Third Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] And please be advised that today’s call is being recorded on Thursday, October 26, 2023.

I would now like to turn the conference over to Edward Chung. Head of Investor Relations. Please go ahead.

Edward Chung

Good afternoon, everyone. Thank you for joining us. Today, we will review the third quarter 2023 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Simon May, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.

Before we begin our review, I’d like to caution everyone that we will be making forward-looking statements about management’s goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today.

Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share which are financial measures that are not defined under generally accepted accounting principles. Investors should review these reconciliations of the non-GAAP financial measures to comparable GAAP results contained in our earnings release.

With that, I will now turn the call over to Andy Last, our Executive Vice President and Chief Operating Officer, to provide an update on Bio-Rad’s global operations.